Literature DB >> 23061342

FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23061342

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  8 in total

1.  Markers of resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Walid Shaib; Reena Mahajan; Bassel El-Rayes
Journal:  J Gastrointest Oncol       Date:  2013-09

2.  Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.

Authors:  Wei-Xiang Qi; Li-Na Tang; Zan Shen; Yang Yao
Journal:  Eur J Clin Pharmacol       Date:  2014-01-05       Impact factor: 2.953

Review 3.  Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.

Authors:  Xi Zhang; Yuge Ran; Yongjie Shao; Kunjie Wang; Yuanxue Zhu
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

Review 4.  Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

Review 5.  Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Fu Shen; Zhang Qing; Guo Xiao-Mao
Journal:  Tumour Biol       Date:  2014-07-30

6.  Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.

Authors:  Takuji Torimura; Hideki Iwamoto; Toru Nakamura; Mitsuhiko Abe; Yu Ikezono; Fumitaka Wada; Takahiko Sakaue; Hiroshi Masuda; Osamu Hashimoto; Hironori Koga; Takato Ueno; Hirohisa Yano
Journal:  Neoplasia       Date:  2016-07       Impact factor: 5.715

7.  Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment.

Authors:  Pu Ge; Ning Wan; Xiao Han; Xinpei Wang; Jinzi Zhang; Xiaoyi Long; Xiaonan Wang; Ying Bian
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

Review 8.  Role of capecitabine in treating metastatic colorectal cancer in Chinese patients.

Authors:  Feng Wang; Feng-Hua Wang; Long Bai; Rui-Hua Xu
Journal:  Onco Targets Ther       Date:  2014-04-02       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.